» Authors » Rawikant Kamolphiwong

Rawikant Kamolphiwong

Explore the profile of Rawikant Kamolphiwong including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 20
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Thongkumkoon P, Sangphukieo A, Tongjai S, Noisagul P, Sangkhathat S, Laochareonsuk W, et al.
Sci Rep . 2024 Sep; 14(1):21092. PMID: 39256458
No abstract available.
2.
Thongkumkoon P, Sangphukieo A, Tongjai S, Noisagul P, Sangkhathat S, Laochareonsuk W, et al.
Sci Rep . 2024 May; 14(1):11056. PMID: 38744935
Osteosarcoma is the most common malignant bone cancer in pediatric patients. Patients who respond poorly to chemotherapy experience worse clinical outcomes with a high mortality rate. The major challenge is...
3.
Kamolphiwong R, Kanokwiroon K, Wongrin W, Chaiyawat P, Klangjorhor J, Settakorn J, et al.
Gene . 2022 Dec; 856:147106. PMID: 36513192
Survival rate of osteosarcoma has remained plateaued for the past three decades. New treatment is needed to improve survival rate. Drug repurposing, a method to identify new indications of previous...
4.
Bissanum R, Kamolphiwong R, Navakanitworakul R, Kanokwiroon K
Transl Cancer Res . 2022 Oct; 11(9):3039-3049. PMID: 36237261
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease associated with late-stage diagnosis and high metastatic rates. However, a gene signature for reliable TNBC biomarkers is not available yet. We...
5.
Sittiju P, Chaiyawat P, Pruksakorn D, Klangjorhor J, Wongrin W, Phinyo P, et al.
Biology (Basel) . 2022 May; 11(5). PMID: 35625426
A liquid biopsy is currently an interesting tool for measuring tumor material with the advantage of being non-invasive. The overexpression of vimentin and ezrin genes was associated with epithelial-mesenchymal transition...
6.
Bissanum R, Chaichulee S, Kamolphiwong R, Navakanitworakul R, Kanokwiroon K
J Pers Med . 2021 Sep; 11(9). PMID: 34575658
Triple negative breast cancer (TNBC) lacks well-defined molecular targets and is highly heterogenous, making treatment challenging. Using gene expression analysis, TNBC has been classified into four different subtypes: basal-like immune-activated...